Serpin Pharma, LLC   Report issue

For profit Phase 2
Founded: Manassas VA United States (2011)

Organization Overview

First Clinical Trial
2018
NCT03651089
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Serpin Pharma, LLC

Active Ingredients

Drugs in Phase 2 Trials (1)

SP16 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infarction (Phase 2)

Inflammation (Phase 2)

Myocardial Infarction (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1